Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949591 | 0.83 | LMNA (0.41) | LMNAMAPTPKMMAP3K14 | |
| SCHEMBL1280223 | 0.82 | LMNA (0.40) | LMNAMAPTPKMMAP3K14 | |
| SCHEMBL7208632 | 0.79 | NPC1 (0.46) | LMNAMAPTPKM | |
| SCHEMBL16049982 | 0.78 | ALDH1A1 (0.39) | LMNAMAPT | |
| SCHEMBL6759523 | 0.78 | HPGD (0.32) | — | |
| SCHEMBL1727857 | 0.78 | GLA (0.32) | — | |
| SCHEMBL3151670 | 0.78 | POLB (0.32) | — | |
| SCHEMBL2037669 | 0.78 | NAAA (0.43) | LMNA | |
| SCHEMBL5816927 | 0.77 | POLB (0.35) | — | |
| SCHEMBL1892476 | 0.75 | ALDH1A1 (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| WO-2014021797-A2 | A CEMENT MATERIAL FOR RENEWAL OF DAMAGED DENTAL TISSUES | MELEK AKMAN (TR) | 2014-02-06 | — | — | WO | claimed |
| JP-9249751-A | — | — | None | — | — | JP | disclosed |
| US-20240239890-A1 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-18 | — | — | US | disclosed |
| US-12024559-B2 | Fusions with CD8 antigen binding molecules for modulating immune cell function | ASHER BIOTHERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3296395-B2 | MULTIPLE ANTIGEN BINDING MOLECULAR FUSION, PHARMACEUTICAL COMPOSITION, METHOD FOR IDENTIFYING LINEAR EPITOPE, AND METHOD FOR PREPARING MULTIPLE ANTIGEN BINDING MOLECULAR FUSION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-06-19 | — | — | EP | disclosed |
| US-20240180150-A1 | Green Closed Loop Bio-waste Refining Process For Producing Smart Active Extracts and Delivery Systems for Their Application | CELLACURE LLC (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4373862-A1 | PROTEASE-MEDIATED TARGET SPECIFIC CYTOKINE DELIVERY USING FUSION POLYPEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3515476-B1 | FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTIEPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER | AMAL THERAPEUTICS SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-20240158785-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240150465-A1 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20060002855-A1 | Targeted combination immunotherapy of cancer and infectious diseases | IMMUNOMEDICS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20030232011-A1 | Targeted combination immunotherapy | IMMUNOMEDICS, INC. | 2003-12-18 | — | — | US | disclosed |
| EP-1351712-A2 | TARGETED COMBINATION IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASES | Immunomedics, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2001097855-A2 | TARGETED COMBINATION IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASES | IMMUNOMEDICS, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| JP-H09249751-A | USE OF HYDROPHOBIC CROSSLINKING AGENT FOR PREPARING CROSSLINKED BIOLOGICAL MATERIAL COMPOSITION | COLLAGN CORP | 1997-09-22 | — | — | JP | disclosed |
| EP-0345723-B1 | Diethylenetriamine pentaacetic acid derivatives | NIHON MEDIPHYSICS CO LTD (JP) | 1994-05-25 | — | — | EP | disclosed |
| US-5250702-A | Nonradioactive carriers for radioactive metal elements | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1993-10-05 | — | — | US | disclosed |
| US-5094950-A | Diagnostics | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1992-03-10 | — | — | US | disclosed |
| EP-0345723-A2 | Diethylenetriamine pentaacetic acid derivatives | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | LMNA 2236/4885MAPT 720/4885PKM 4311/4885 |
| US-20240158785-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | MICA, CD69, CD74 | LMNA 4807/4885MAPT 1971/4885PKM 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.